This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroToday Home
Video Lectures
ASCO 2024 Videos
Antibody Drug Conjugate FOR46: Targeting CD46 in mCRPC in Phase 1b Trial - Nonna Shakhnazaryan
The Best of ASCO 2024 in Advanced Bladder Cancer - Shilpa Gupta
Small Cell Neuroendocrine Carcinoma of Urinary Tract: Relapse Factors & Treatment - Omar Alhalabi
PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life - Karim Fizazi
PROSTATE-IQ Trial: Reducing ADT Burden in Salvage Radiotherapy - Karen Hoffman
ENLIGHTED Trial Advances Upper Tract Urothelial Cancer Treatment - Vitaly Margulis
Understanding KEYNOTE-564: Pembrolizumab’s Role and Post-Adjuvant Therapy for RCC Patients - Karl Semaan & Talal El Zarif
MAST Trial Finds Metformin Ineffective in Preventing Prostate Cancer Progression - Neil Fleshner
VA's Million Veterans Program Reveals Crucial Genetic Data for Prostate Cancer Treatment - Bruce Montgomery
Mentorship and Opportunity: Keys to Success in Medicine - Veda Giri
SECuRE Trial: Copper-67 SAR-bisPSMA Therapy for Prostate Cancer - Geoffrey Johnson
Genomic Alterations and Lutetium PSMA Response in Prostate Cancer - Alexandra Sokolova
CYCLONE 2 Trial Results: Abemaciclib in Metastatic Castration-Resistant Prostate Cancer - Matthew Smith
Prostate Cancer Diversity Revealed: AR and Neuroendocrine Signatures - Yu-Wei Chen
Breaking Barriers in Cancer Treatment and Women's Leadership in Oncology - Ulka Vaishampayan
Mental Health and Prostate Cancer in the Veterans Population - Zachary Klaassen
BRCA2 and Beyond: Unraveling Genetic Drivers of Prostate Cancer Aggressiveness - Hiba Khan
SunRISe-5 Trial: Evaluating TAR-200 for Recurrent High-Risk Non-Muscle Invasive Bladder Cancer - Sima Porten
IMPLEMENT Study: Addressing the Underutilization of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer - Stacy Loeb
Targeting EZH2 in Prostate Cancer: The Role of Mevrometostat in Preventing Neuroendocrine Differentiation - Michael Schweizer
Machine Learning Model Predicts Overall Survival in Metastatic Prostate Cancer - Ali Sabbagh
Tarlatamab Shows Encouraging Activity in Phase 1 Trial in DLL3-Positive Neuroendocrine Prostate Cancer - Rahul Aggarwal
ctDNA Fraction Predicts Response to Lutetium PSMA in TheraP Trial for mCRPC - Edmond Kwan
ARAMIS Trial: PSA Responses with Darolutamide Linked to Minimal Radiographic Progression - Alicia Morgans
Testicular Cancer Treatment and Cardiovascular Health: Understanding the Long-Term Risks - Khalid Alkhatib
Enzalutamide Plus 5-Alpha Reductase Inhibitors for Castrate-Sensitive Prostate Cancer: A Phase 2 Trial - Deepak Kilari
Dose-Escalation of Lutetium PSMA: Final Results from a Phase I/II Trial - Scott Tagawa
MAST Trial: Investigating Metformin's Role in Prostate Cancer Active Surveillance - Anthony Joshua
Exploring Genetic Counseling in Veterans with Advanced Prostate Cancer - Daniel Kwon
Advancing Treatment for High-Risk Biochemical Recurrence Prostate Cancer: The ARASTEP Trial - Alexander Chehrazi-Raffle
EV-302 Subgroup Analysis: Improved Outcomes for Cisplatin-Ineligible Advanced Urothelial Cancer Patients - Michiel Van der Heijden
Cretostimogene Grenadenorepvec: A Novel Oncolytic Immunotherapy for BCG-Unresponsive NMIBC - Roger Li
Prognostic Power of Multi-Modal Artificial Intelligence Biomarker in CHAARTED Trial Subset - Mark Markowski
OASIS Project Highlights the Survival Benefits of Rapid PSA Decline with Apalutamide in Prostate Cancer - Benjamin Maughan
ARV-766: Efficacy and Safety of a Second-Generation AR Degrader in Prostate Cancer - Daniel Petrylak
CHAARTED 2 Study Shows PFS Benefit with Cabazitaxel in Metastatic Prostate Cancer in Phase 2 - Christos Kyriakopoulos
Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication - Susan Halabi
PROMISE Criteria: Enhanced Survival Prediction in Prostate Cancer with PSMA PET - Wolfgang Fendler
hK2-Targeted Radioligand Shows Promise in Treating Advanced Prostate Cancer: Phase I Findings - Michael Morris
Predicting Response to Bipolar Androgen Therapy: A Blood-Based Biomarker Approach - Samuel Denmeade
CORE-001 Study Demonstrates Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab - Trinity Bivalacqua & Roger Li
Behavioral Interventions for Mitigating ADT Side Effects in Prostate Cancer - Brian Gonzalez
Antibody Drug Conjugate FOR46: Targeting CD46 in mCRPC in Phase 1b Trial - Nonna Shakhnazaryan
The Best of ASCO 2024 in Advanced Bladder Cancer - Shilpa Gupta
Small Cell Neuroendocrine Carcinoma of Urinary Tract: Relapse Factors & Treatment - Omar Alhalabi
PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life - Karim Fizazi
PROSTATE-IQ Trial: Reducing ADT Burden in Salvage Radiotherapy - Karen Hoffman
ENLIGHTED Trial Advances Upper Tract Urothelial Cancer Treatment - Vitaly Margulis
Understanding KEYNOTE-564: Pembrolizumab’s Role and Post-Adjuvant Therapy for RCC Patients - Karl Semaan & Talal El Zarif
MAST Trial Finds Metformin Ineffective in Preventing Prostate Cancer Progression - Neil Fleshner
VA's Million Veterans Program Reveals Crucial Genetic Data for Prostate Cancer Treatment - Bruce Montgomery
Mentorship and Opportunity: Keys to Success in Medicine - Veda Giri
SECuRE Trial: Copper-67 SAR-bisPSMA Therapy for Prostate Cancer - Geoffrey Johnson
Genomic Alterations and Lutetium PSMA Response in Prostate Cancer - Alexandra Sokolova
CYCLONE 2 Trial Results: Abemaciclib in Metastatic Castration-Resistant Prostate Cancer - Matthew Smith
Prostate Cancer Diversity Revealed: AR and Neuroendocrine Signatures - Yu-Wei Chen
Breaking Barriers in Cancer Treatment and Women's Leadership in Oncology - Ulka Vaishampayan
Mental Health and Prostate Cancer in the Veterans Population - Zachary Klaassen
BRCA2 and Beyond: Unraveling Genetic Drivers of Prostate Cancer Aggressiveness - Hiba Khan
SunRISe-5 Trial: Evaluating TAR-200 for Recurrent High-Risk Non-Muscle Invasive Bladder Cancer - Sima Porten
IMPLEMENT Study: Addressing the Underutilization of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer - Stacy Loeb
Targeting EZH2 in Prostate Cancer: The Role of Mevrometostat in Preventing Neuroendocrine Differentiation - Michael Schweizer
Machine Learning Model Predicts Overall Survival in Metastatic Prostate Cancer - Ali Sabbagh
Tarlatamab Shows Encouraging Activity in Phase 1 Trial in DLL3-Positive Neuroendocrine Prostate Cancer - Rahul Aggarwal
ctDNA Fraction Predicts Response to Lutetium PSMA in TheraP Trial for mCRPC - Edmond Kwan
ARAMIS Trial: PSA Responses with Darolutamide Linked to Minimal Radiographic Progression - Alicia Morgans
Testicular Cancer Treatment and Cardiovascular Health: Understanding the Long-Term Risks - Khalid Alkhatib
Enzalutamide Plus 5-Alpha Reductase Inhibitors for Castrate-Sensitive Prostate Cancer: A Phase 2 Trial - Deepak Kilari
Dose-Escalation of Lutetium PSMA: Final Results from a Phase I/II Trial - Scott Tagawa
MAST Trial: Investigating Metformin's Role in Prostate Cancer Active Surveillance - Anthony Joshua
Exploring Genetic Counseling in Veterans with Advanced Prostate Cancer - Daniel Kwon
Advancing Treatment for High-Risk Biochemical Recurrence Prostate Cancer: The ARASTEP Trial - Alexander Chehrazi-Raffle
EV-302 Subgroup Analysis: Improved Outcomes for Cisplatin-Ineligible Advanced Urothelial Cancer Patients - Michiel Van der Heijden
Cretostimogene Grenadenorepvec: A Novel Oncolytic Immunotherapy for BCG-Unresponsive NMIBC - Roger Li
Prognostic Power of Multi-Modal Artificial Intelligence Biomarker in CHAARTED Trial Subset - Mark Markowski
OASIS Project Highlights the Survival Benefits of Rapid PSA Decline with Apalutamide in Prostate Cancer - Benjamin Maughan
ARV-766: Efficacy and Safety of a Second-Generation AR Degrader in Prostate Cancer - Daniel Petrylak
CHAARTED 2 Study Shows PFS Benefit with Cabazitaxel in Metastatic Prostate Cancer in Phase 2 - Christos Kyriakopoulos
Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication - Susan Halabi
PROMISE Criteria: Enhanced Survival Prediction in Prostate Cancer with PSMA PET - Wolfgang Fendler
hK2-Targeted Radioligand Shows Promise in Treating Advanced Prostate Cancer: Phase I Findings - Michael Morris
Predicting Response to Bipolar Androgen Therapy: A Blood-Based Biomarker Approach - Samuel Denmeade
CORE-001 Study Demonstrates Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab - Trinity Bivalacqua & Roger Li
Behavioral Interventions for Mitigating ADT Side Effects in Prostate Cancer - Brian Gonzalez
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
